Stockscreener 앱 받기
124.44
5.46%
-7.19
시간 외 거래:
124.50
0.06
+0.05%
Abbott Laboratories 주식(ABT)의 최신 뉴스
Here’s What to Expect From Abbott Laboratories’ Next Earnings Report - Nasdaq
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic? - Yahoo
Piper Sandler maintains Overweight on Abbott Labs with $133 target - Investing.com
Reasons to Add ABT Stock to Your Portfolio Right Now - TradingView
Q4 Rundown: Abbott Laboratories (NYSE:ABT) Vs Other Medical Devices & SuppliesDiversified Stocks - Yahoo Finance
Unsanitary Practices Persist at Baby Formula Factory Whose Shutdown Led to Mass Shortages, Workers Say - ProPublica
Leadless Pacemakers Market Deep Research 2025-2032 | Abbott - openPR.com
Global Expansion in EPD and Innovations Support Abbott Stock - TradingView
Similac infant formula class action alleges products contain heavy metals - Class Action Lawsuits
FISH Probe Market Is Booming So Rapidly 2025-2032Abbott Laboratories, Agilent Technologies Inc - openPR.com
Hematology Diagnostics Market is Booming Worldwide | Abbott, Boule Diagnostics, and Danaher are the Major Stakeholders – Arizton - Barchart.com
Abbott Laboratories consolidates media with Spark Foundry - Ad Age
Abbott launches next-gen delivery system for Proclaim DRG neurostim - MassDevice
Personalized Medicine Market Growth Trends 2025-2033: Transition to Customized Medical Care, Developments in Bioinformatics and Genomics, Growing Prevalence of Chronic Diseases - GlobeNewswire Inc.
Abbott joins AFib-treating race with tech that may skip general anesthesia - Star Tribune
Abbott Laboratories (NYSE:ABT) Shows Promising Results in Heart Valve Device Study - simplywall.st
Hematology Market Is Booming Worldwide | Abbott Laboratories, Sysmex Co., Beckman Coulter, Horiba - openPR.com
ABT Stock Gains Following the Positive TRILUMINATE Trial Results - TradingView
ABC's 'Abbott Elementary' teams up with MilliporeSigma to bring mobile science lab to San Jose elementary school students - ABC7 San Francisco
Abbott (ABT) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Sector Update: Health Care Stocks Mixed in Afternoon Trading - MarketScreener
Abbott Laboratories’ TriClip Device: A Promising Investment Backed by Positive TRILUMINATE Trial Results - TipRanks
Abbott TriClip offers substantial improvements in study - MassDevice
Abbott Laboratories Says Trial Results Show Benefits of TriClip System for People With Leaky Heart Valves - MarketScreener
The Zacks Analyst Blog Highlights McDonald's, Abbott Laboratories, O'Reilly Automotive and MIND Technology - Yahoo Finance
Abbott's Revolutionary Heart Valve Treatment Cuts Hospitalizations by 27% in Landmark Trial - Stock Titan
Abbott Laboratories’ SWOT analysis: stock outlook amid PFA system approval - Investing.com
Why Abbott Laboratories Stock Leaped by Almost 4% on Thursday - MSN
3 Relatively Safe Stocks to Buy Right Now - The Motley Fool
Top Research Reports for McDonald's, Abbott & O'Reilly Automotive - Yahoo Finance
Abbott snags early CE mark for Volt PFA device - MedTech Dive
$11.66 Bn Lateral Flow Assays Market Insights 2025-2030 with Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, QuidelOrtho, and PerkinElmer DominatingResearchAndMarkets.com - Bluefield Daily Telegraph
Is Abbott Laboratories (ABT) the Best S&P 500 Stock to Buy for Dividend Growth? - Yahoo Finance
Abbott Laboratories: Promising Growth Potential with Early CE Mark Approval and Strong PFA Technology Outlook - TipRanks
Abbott Laboratories' (NYSE:ABT) five-year earnings growth trails the 13% YoY shareholder returns - Yahoo Finance
Why Abbott Laboratories (ABT) Surged On Thursday? - Insider Monkey
Abbott (ABT) Stock Rises on European Approval - GuruFocus
Abbott Laboratories stock outperforms competitors on strong trading day - MSN
Abbott’s Volt enters the PFA fray with CE mark - BioWorld MedTech
Abbott Secures CE Mark for Volt PFA System, Advancing in Competitive PFA Market - Medical Device and Diagnostic industry
Abbott wins CE Mark for Volt PFA system to treat atrial fibrillation, begins EU rollout - MassDevice
Abbott Receives CE Mark for Pulsed Field Ablation System - Diagnostic and Interventional Cardiology
Oppenheimer maintains Abbott Labs target at $134 on CE Mark nod - Investing.com
Abbott accelerates PFA market competition in Europe with early Volt approval - Medical Device Network
Abbott's new AFib device gets early OK from European regulators - Crain's Chicago Business
May 9th Options Now Available For Abbott Laboratories (ABT) - Nasdaq
BTIG maintains Buy on Abbott Labs stock, $140 target - Investing.com India
Abbott gains CE mark approval for Volt PFA system - Cardiovascular Business
Abbott Laboratories Receives CE Mark Certification for Volt Pulsed Field Ablation System - Marketscreener.com
Abbott Laboratories (ABT): Among Dividend Zombies to Invest in - Insider Monkey
Abbott’s Volt Pulsed Field Ablation Nabs EU Approval - MPO-mag
Abbott’s Volt PFA system gains CE Mark for AFib treatment By Investing.com - Investing.com Australia
Abbott’s Volt PFA system gains CE Mark for AFib treatment - Investing.com
Abbott Receives CE Mark For Its Volt(TM) Pulsed Field Ablation System To Treat Patients With Abnormal Heart Rhythms - MarketScreener
6.07%
자본화:
|
볼륨(24시간):